West Pharmaceutical Services, Inc.
Rank #240Capital ReturnWST · NYSE · Healthcare
West Pharmaceutical Services, Inc. (WST) — Rank #240 by gross profitability (GP/assets 0.27) · ROE 16.5% · Piotroski F-Score 7 / 9.
As-of 2026-09-28 · CIK 0000105770 · all metrics point-in-time as of the filing date.
About
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Show moreShow less
It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc.
was founded in 1923 and is headquartered in Exton, Pennsylvania.
- Industry
- Medical Instruments & Supplies
- Sector
- Healthcare
- State
- PA
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- westpharma.com
Company Snapshot
P/E and reverse DCF are the primary valuation lenses at this stage.
Market Cap
—
P/E (annual)
—
P/S (annual)
—
P/B
—
P/OCF (annual)
—
Shareholder Yield
—
Employees
10,800
Industry
Medical Instruments & Supplies
Exchange
NYSE
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
2/3 passGrowth
2/2 passTerry Smith quality gate
Passes 1/5 Terry Smith thresholds1 of 5 threshold not computable from filed data.
FCF yield, shareholder yield, and buyback activity are the primary reads at this stage.
Profitability
Gross profitability (GP / assets)
0.27
Primary signal (Novy-Marx).
16th pctl of 20 SIC 3841 peers
Return on equity
16.5%
Gross margin
35.9%
0th pctl of 20 SIC 3841 peers
Revenue growth (YoY)
6.3%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
2.1%
Revenue CAGR (5Y)
7.4%
Earnings CAGR (3Y)
-5.5%
FCF CAGR (3Y)
2.2%
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.36
7th of 19 SIC 3841 peers (best = lowest)
Current ratio
2.82×
47th pctl of 20 SIC 3841 peers
Quick ratio
1.79×
Net cash
$232.90M
Cash & equivalents minus total debt.
Recession resistance
Revenue through recessions
Worst single-year YoY revenue decline, 18 years of history
Cash-flow health
Free cash flow
$468.90M
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
-0.05
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
0.8%
Stock-based comp intensity.
Dividend safety
Composite score
4.2 / 5
Piotroski F-Score
F-Score
7 / 9
Fundamental-strength score (0-9).